APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microarray-based Non-Invasive Prenatal Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Microarray-based Non-Invasive Prenatal Testing Market Outlook and Growth Opportunities 2026

3 May 2026192 pages

Choose your research edition.

Industry ResearchMicroarray-based Non-Invasive Prenatal Testing Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Microarray-based Non-Invasive Prenatal Testing Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Microarray-based Non-Invasive Prenatal Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microarray-based Non-Invasive Prenatal Testing Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Microarray-based Non-Invasive Prenatal Testing Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Microarray-based Non-Invasive Prenatal Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Microarray-based Non-Invasive Prenatal Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Microarray-based Non-Invasive Prenatal Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Microarray-based Non-Invasive Prenatal Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Microarray-based Non-Invasive Prenatal Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Microarray-based Non-Invasive Prenatal Testing market include Agilent Technologies, Ariosa Diagnostics (Roche), BGI Group, Eurofins LifeCodexx GmbH, Illumina, Laboratory Corporation of America, Myriad Genetics, Natera and PerkinElmer Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Microarray-based Non-Invasive Prenatal Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Microarray-based Non-Invasive Prenatal Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Microarray-based Non-Invasive Prenatal Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Microarray-based Non-Invasive Prenatal Testing market.

Microarray-based Non-Invasive Prenatal Testing Segment by Company

Agilent Technologies

Ariosa Diagnostics (Roche)

BGI Group

Eurofins LifeCodexx GmbH

Illumina

Laboratory Corporation of America

Myriad Genetics

Natera

PerkinElmer Inc

Quest Diagnostics

Sequenom

Microarray-based Non-Invasive Prenatal Testing Segment by Type

Trisomy Detection

Microdeletion Syndromes

Other

Microarray-based Non-Invasive Prenatal Testing Segment by Application

Hospitals & Clinics

Independent Laboratories

Microarray-based Non-Invasive Prenatal Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Microarray-based Non-Invasive Prenatal Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Microarray-based Non-Invasive Prenatal Testing key companies, revenue, market share, and recent developments.

3. To split the Microarray-based Non-Invasive Prenatal Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Microarray-based Non-Invasive Prenatal Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Microarray-based Non-Invasive Prenatal Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Microarray-based Non-Invasive Prenatal Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microarray-based Non-Invasive Prenatal Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microarray-based Non-Invasive Prenatal Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microarray-based Non-Invasive Prenatal Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microarray-based Non-Invasive Prenatal Testing industry.

Chapter 3: Detailed analysis of Microarray-based Non-Invasive Prenatal Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Microarray-based Non-Invasive Prenatal Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Microarray-based Non-Invasive Prenatal Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Microarray-based Non-Invasive Prenatal Testing Industry Trends Table 2. Microarray-based Non-Invasive Prenatal Testing Industry Drivers Table 3. Microarray-based Non-Invasive Prenatal Testing Industry Opportunities and Challenges Table 4. Microarray-based Non-Invasive Prenatal Testing Industry Restraints Table 5. Global Microarray-based Non-Invasive Prenatal Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Microarray-based Non-Invasive Prenatal Testing Revenue Share by Company (2021-2026) Table 7. Global Microarray-based Non-Invasive Prenatal Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Microarray-based Non-Invasive Prenatal Testing Key Company Manufacturing Base & Headquarters Table 9. Global Microarray-based Non-Invasive Prenatal Testing Company, Product Type & Application Table 10. Global Microarray-based Non-Invasive Prenatal Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Microarray-based Non-Invasive Prenatal Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Trisomy Detection Table 15. Significant Companies of Microdeletion Syndromes Table 16. Significant Companies of Other Table 17. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type (2021-2026) Table 21. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals & Clinics Table 23. Significant Companies of Independent Laboratories Table 24. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application (2021-2026) Table 28. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application (2027-2032) Table 29. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Region (2021-2026) Table 32. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Region (2027-2032) Table 34. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Market Share by Country (2021-2026) Table 37. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Market Share by Country (2027-2032) Table 39. Agilent Technologies Company Information Table 40. Agilent Technologies Business Overview Table 41. Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 43. Agilent Technologies Recent Development Table 44. Ariosa Diagnostics (Roche) Company Information Table 45. Ariosa Diagnostics (Roche) Business Overview Table 46. Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 48. Ariosa Diagnostics (Roche) Recent Development Table 49. BGI Group Company Information Table 50. BGI Group Business Overview Table 51. BGI Group Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. BGI Group Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 53. BGI Group Recent Development Table 54. Eurofins LifeCodexx GmbH Company Information Table 55. Eurofins LifeCodexx GmbH Business Overview Table 56. Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 58. Eurofins LifeCodexx GmbH Recent Development Table 59. Illumina Company Information Table 60. Illumina Business Overview Table 61. Illumina Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Illumina Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 63. Illumina Recent Development Table 64. Laboratory Corporation of America Company Information Table 65. Laboratory Corporation of America Business Overview Table 66. Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 68. Laboratory Corporation of America Recent Development Table 69. Myriad Genetics Company Information Table 70. Myriad Genetics Business Overview Table 71. Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 73. Myriad Genetics Recent Development Table 74. Natera Company Information Table 75. Natera Business Overview Table 76. Natera Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Natera Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 78. Natera Recent Development Table 79. PerkinElmer Inc Company Information Table 80. PerkinElmer Inc Business Overview Table 81. PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 83. PerkinElmer Inc Recent Development Table 84. Quest Diagnostics Company Information Table 85. Quest Diagnostics Business Overview Table 86. Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 88. Quest Diagnostics Recent Development Table 89. Sequenom Company Information Table 90. Sequenom Business Overview Table 91. Sequenom Microarray-based Non-Invasive Prenatal Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Sequenom Microarray-based Non-Invasive Prenatal Testing Product Portfolio Table 93. Sequenom Recent Development Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Microarray-based Non-Invasive Prenatal Testing Product Image Figure 2. Global Microarray-based Non-Invasive Prenatal Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Microarray-based Non-Invasive Prenatal Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Trisomy Detection Image Figure 8. Microdeletion Syndromes Image Figure 9. Other Image Figure 10. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type (2021-2032) Figure 13. Hospitals & Clinics Image Figure 14. Independent Laboratories Image Figure 15. Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application (2021-2032) Figure 18. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032) & (US$ Million) Figure 21. North America Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032) & (US$ Million) Figure 27. South America Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Trisomy Detection
  • Microdeletion Syndromes
  • Other
Applications
  • Hospitals & Clinics
  • Independent Laboratories
Companies covered
  • Agilent Technologies
  • Ariosa Diagnostics (Roche)
  • BGI Group
  • Eurofins LifeCodexx GmbH
  • Illumina
  • Laboratory Corporation of America
  • Myriad Genetics
  • Natera
  • PerkinElmer Inc
  • Quest Diagnostics
  • Sequenom

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Microarray-based Non-Invasive Prenatal Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Microarray-based Non-Invasive Prenatal Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Microarray-based Non-Invasive Prenatal Testing Market Dynamics
  1. 2.1 Microarray-based Non-Invasive Prenatal Testing Industry Trends
  2. 2.2 Microarray-based Non-Invasive Prenatal Testing Industry Drivers
  3. 2.3 Microarray-based Non-Invasive Prenatal Testing Industry Opportunities and Challenges
  4. 2.4 Microarray-based Non-Invasive Prenatal Testing Industry Restraints
3 Microarray-based Non-Invasive Prenatal Testing Market by Company
  1. 3.1 Global Microarray-based Non-Invasive Prenatal Testing Company Revenue Ranking in 2025
  2. 3.2 Global Microarray-based Non-Invasive Prenatal Testing Revenue by Company (2021-2026)
  3. 3.3 Global Microarray-based Non-Invasive Prenatal Testing Company Ranking (2024-2026)
  4. 3.4 Global Microarray-based Non-Invasive Prenatal Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Microarray-based Non-Invasive Prenatal Testing Company Product Type and Application
  6. 3.6 Global Microarray-based Non-Invasive Prenatal Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Microarray-based Non-Invasive Prenatal Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Microarray-based Non-Invasive Prenatal Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Microarray-based Non-Invasive Prenatal Testing Market by Type
  1. 4.1 Microarray-based Non-Invasive Prenatal Testing Type Introduction
  2. 4.1.1 Trisomy Detection
  3. 4.1.2 Microdeletion Syndromes
  4. 4.1.3 Other
  5. 4.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type
  6. 4.2.1 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Type (2021-2032)
  8. 4.2.3 Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type (2021-2032)
5 Microarray-based Non-Invasive Prenatal Testing Market by Application
  1. 5.1 Microarray-based Non-Invasive Prenatal Testing Application Introduction
  2. 5.1.1 Hospitals & Clinics
  3. 5.1.2 Independent Laboratories
  4. 5.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application
  5. 5.2.1 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Application (2021-2032)
  7. 5.2.3 Global Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application (2021-2032)
6 Microarray-based Non-Invasive Prenatal Testing Regional Value Analysis
  1. 6.1 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032)
  7. 6.3.2 North America Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032)
  16. 6.6.2 South America Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Country, 2025 VS 2032
7 Microarray-based Non-Invasive Prenatal Testing Country-level Value Analysis
  1. 7.1 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Microarray-based Non-Invasive Prenatal Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Microarray-based Non-Invasive Prenatal Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Microarray-based Non-Invasive Prenatal Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Agilent Technologies
  2. 8.1.1 Agilent Technologies Company Information
  3. 8.1.2 Agilent Technologies Business Overview
  4. 8.1.3 Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Agilent Technologies Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  6. 8.1.5 Agilent Technologies Recent Developments
  7. 8.2 Ariosa Diagnostics (Roche)
  8. 8.2.1 Ariosa Diagnostics (Roche) Company Information
  9. 8.2.2 Ariosa Diagnostics (Roche) Business Overview
  10. 8.2.3 Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ariosa Diagnostics (Roche) Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  12. 8.2.5 Ariosa Diagnostics (Roche) Recent Developments
  13. 8.3 BGI Group
  14. 8.3.1 BGI Group Company Information
  15. 8.3.2 BGI Group Business Overview
  16. 8.3.3 BGI Group Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BGI Group Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  18. 8.3.5 BGI Group Recent Developments
  19. 8.4 Eurofins LifeCodexx GmbH
  20. 8.4.1 Eurofins LifeCodexx GmbH Company Information
  21. 8.4.2 Eurofins LifeCodexx GmbH Business Overview
  22. 8.4.3 Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eurofins LifeCodexx GmbH Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  24. 8.4.5 Eurofins LifeCodexx GmbH Recent Developments
  25. 8.5 Illumina
  26. 8.5.1 Illumina Company Information
  27. 8.5.2 Illumina Business Overview
  28. 8.5.3 Illumina Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Illumina Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  30. 8.5.5 Illumina Recent Developments
  31. 8.6 Laboratory Corporation of America
  32. 8.6.1 Laboratory Corporation of America Company Information
  33. 8.6.2 Laboratory Corporation of America Business Overview
  34. 8.6.3 Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Laboratory Corporation of America Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  36. 8.6.5 Laboratory Corporation of America Recent Developments
  37. 8.7 Myriad Genetics
  38. 8.7.1 Myriad Genetics Company Information
  39. 8.7.2 Myriad Genetics Business Overview
  40. 8.7.3 Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Myriad Genetics Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  42. 8.7.5 Myriad Genetics Recent Developments
  43. 8.8 Natera
  44. 8.8.1 Natera Company Information
  45. 8.8.2 Natera Business Overview
  46. 8.8.3 Natera Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Natera Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  48. 8.8.5 Natera Recent Developments
  49. 8.9 PerkinElmer Inc
  50. 8.9.1 PerkinElmer Inc Company Information
  51. 8.9.2 PerkinElmer Inc Business Overview
  52. 8.9.3 PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 PerkinElmer Inc Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  54. 8.9.5 PerkinElmer Inc Recent Developments
  55. 8.10 Quest Diagnostics
  56. 8.10.1 Quest Diagnostics Company Information
  57. 8.10.2 Quest Diagnostics Business Overview
  58. 8.10.3 Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Quest Diagnostics Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  60. 8.10.5 Quest Diagnostics Recent Developments
  61. 8.11 Sequenom
  62. 8.11.1 Sequenom Company Information
  63. 8.11.2 Sequenom Business Overview
  64. 8.11.3 Sequenom Microarray-based Non-Invasive Prenatal Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sequenom Microarray-based Non-Invasive Prenatal Testing Product Portfolio
  66. 8.11.5 Sequenom Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst